Canland Health Announces Non-Brokered Private Placement and Seed Share Closing

VANCOUVER, BC / ACCESSWIRE / October 17, 2019 / Canland Health Corp. (the “Company”) today announced that it intends to arrange the placement of up to 3,650,000 common shares priced at $0.10 per common share for total gross proceeds of up to $365,000 (the “Offering”). Proceeds from the Offering shall be used for investigating project acquisitions and general corporate purposes. The Offering is subject to regulatory approval and all securities to be issued pursuant to the Offering are subject to a four-month hold period under applicable Canadian securities laws.

The Company further announced that it has closed a previously announced seed share issuance of 4,600,000 common shares at a price per share of $0.005 for gross proceeds of $23,000 (the “Seed Share Issuance”). The common shares issued pursuant to the Seed Share Issuance are subject to a four month hold expiring on February 8, 2020.

For further information regarding this news release contact:

C.K. Cheung, CEO
Tel: 416 904 1478

On behalf of the Board of Directors

CANLAND HEALTH CORP.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO SELL ANY OF THE SECURITIES DESCRIBED HEREIN IN THE UNITED STATES. THESE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE UNITED STATED SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

SOURCE: Canland Health Corp.

View source version on accesswire.com:
https://www.accesswire.com/563436/Canland-Health-Announces-Non-Brokered-Private-Placement-and-Seed-Share-Closing

Staff

Recent Posts

Creative Medical Technology Holdings Provides Corporate Update

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a…

2 hours ago

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

Prostate Volume Assist (PVA) is the company’s proprietary urology-based artificial intelligence (AI) software feature designed…

2 hours ago

Sutter Health Partners with Abridge on Generative AI Solution to Improve Patient, Physician Experience

PITTSBURGH & SACRAMENTO, Calif.--(BUSINESS WIRE)--Today, Abridge and Sutter Health announced they will make Abridge’s generative…

2 hours ago

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Presentations Will Feature Studies Evaluating TENEO™ Excimer Laser Platform, MIEBO® (Perfluorohexyloctane Ophthalmic Solution) and enVista®…

2 hours ago

Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

Blackstone Life Sciences to invest up to $750 million to support innovative mRNA technologyNEW YORK--(BUSINESS…

2 hours ago

Male Contraceptive Initiative Marks Women’s History Month With Investment in Birth Control Pill for Men

Phase 1a study of first hormone-free male pill completes enrollmentDURHAM, NC / ACCESSWIRE / March…

2 hours ago